RecruitingPHASE2, PHASE3NCT07068165

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

Studying IgG4-related disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking Union Medical College Hospital
Intervention
5mg lenalidomide(drug)
Enrollment
198 enrolled
Eligibility
18-75 years · All sexes
Timeline
2025 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07068165 on ClinicalTrials.gov

Other trials for IgG4-related disease

Additional recruiting or active studies for the same condition.

See all trials for IgG4-related disease →

← Back to all trials